Total Payments
$33,253
2024 Payments
$9,034
Companies
28
Transactions
94
Medicare Patients
42,307
Medicare Billing
$17.2M
Payment Breakdown by Category
Other$23,625 (71.0%)
Travel$4,801 (14.4%)
Consulting$2,938 (8.8%)
Food & Beverage$1,761 (5.3%)
Education$128.07 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,625 | 11 | 71.0% |
| Travel and Lodging | $4,801 | 13 | 14.4% |
| Consulting Fee | $2,938 | 2 | 8.8% |
| Food and Beverage | $1,761 | 65 | 5.3% |
| Education | $128.07 | 3 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20,496 | 26 | $0 (2024) |
| Amgen Inc. | $10,187 | 12 | $0 (2019) |
| Eli Lilly and Company | $1,438 | 1 | $0 (2021) |
| Lilly USA, LLC | $155.87 | 9 | $0 (2023) |
| Eisai Inc. | $151.74 | 3 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $102.32 | 1 | $0 (2018) |
| PFIZER INC. | $82.79 | 5 | $0 (2024) |
| GENZYME CORPORATION | $76.99 | 4 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $70.62 | 4 | $0 (2024) |
| Daiichi Sankyo Inc. | $58.01 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,034 | 28 | Merck Sharp & Dohme LLC ($8,776) |
| 2023 | $112.98 | 6 | Eisai Inc. ($23.26) |
| 2022 | $35.84 | 2 | Lilly USA, LLC ($19.40) |
| 2021 | $1,506 | 5 | Eli Lilly and Company ($1,438) |
| 2020 | $82.29 | 4 | Lilly USA, LLC ($43.04) |
| 2019 | $12,874 | 23 | Merck Sharp & Dohme Corporation ($11,693) |
| 2018 | $6,225 | 12 | Amgen Inc. ($6,017) |
| 2017 | $3,382 | 14 | Amgen Inc. ($3,250) |
All Payment Transactions
94 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: ONC | ||||||
| 11/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $874.94 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $303.16 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $122.55 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.67 | General |
| 11/05/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: VACCINES | ||||||
| 07/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/23/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: VACCINES | ||||||
| 05/22/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 05/16/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Hematology | ||||||
| 05/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Oncology | ||||||
| 04/05/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| 04/05/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Hematology | ||||||
| 04/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $40.25 | General |
| Category: ONCOLOGY | ||||||
| 03/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $348.21 | General |
| Category: ONCOLOGY | ||||||
| 03/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $149.00 | General |
| Category: ONCOLOGY | ||||||
| 03/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $88.08 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 102 | 9,867 | 196,410 | $17.3M | $3.9M |
| 2022 | 109 | 10,746 | 264,943 | $20.7M | $4.4M |
| 2021 | 104 | 10,151 | 215,373 | $15.5M | $3.5M |
| 2020 | 110 | 11,543 | 384,154 | $23.3M | $5.3M |
Total Patients
42,307
Total Services
1,060,880
Medicare Billing
$17.2M
Procedure Codes
425
All Medicare Procedures & Services
425 procedure records from CMS Medicare Utilization — Page 1 of 17
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 69 | 33,600 | $6.3M | $1.5M | 22.9% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 28 | 10,080 | $1.6M | $382,672 | 23.4% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 26 | 14,740 | $1.5M | $331,810 | 21.5% |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | Office | 2023 | 12 | 8,200 | $738,164 | $167,730 | 22.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 77 | 8,700 | $612,219 | $158,618 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 762 | 1,657 | $677,589 | $143,622 | 21.2% |
| J9047 | Injection, carfilzomib, 1 mg | Office | 2023 | 13 | 3,970 | $620,509 | $142,274 | 22.9% |
| J9173 | Injection, durvalumab, 10 mg | Office | 2023 | 11 | 1,830 | $505,373 | $113,728 | 22.5% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 13 | 2,520 | $554,556 | $107,091 | 19.3% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 25 | 2,680 | $425,992 | $93,734 | 22.0% |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | Office | 2023 | 12 | 530 | $381,474 | $80,649 | 21.1% |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2023 | 25 | 3,480 | $386,071 | $79,352 | 20.6% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 12 | 2,244 | $275,788 | $57,013 | 20.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 341 | 572 | $259,172 | $52,926 | 20.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 77 | 21,400 | $235,726 | $50,057 | 21.2% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 13 | 1,050 | $182,837 | $37,607 | 20.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 103 | 515 | $36,050 | $36,652 | 101.7% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 11 | 3,600 | $150,876 | $35,113 | 23.3% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 19 | 348 | $167,397 | $31,135 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 152 | 216 | $124,093 | $28,216 | 22.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 910 | 2,920 | $79,424 | $22,081 | 27.8% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 891 | 2,603 | $77,075 | $21,423 | 27.8% |
| 80076 | Liver function blood test panel | Office | 2023 | 877 | 2,507 | $71,700 | $19,943 | 27.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 50 | 60 | $100,481 | $19,832 | 19.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 29 | 22,500 | $86,850 | $19,743 | 22.7% |
About Dr. Kurt Tauer, MD
Dr. Kurt Tauer, MD is a Medical Oncology healthcare provider based in Germantown, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053340802.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kurt Tauer, MD has received a total of $33,253 in payments from pharmaceutical and medical device companies, with $9,034 received in 2024. These payments were reported across 94 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($23,625).
As a Medicare-enrolled provider, Tauer has provided services to 42,307 Medicare beneficiaries, totaling 1,060,880 services with total Medicare billing of $17.2M. Data is available for 4 years (2020–2023), covering 425 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Germantown, TN
- Active Since 07/02/2006
- Last Updated 02/21/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1053340802
Products in Payments
- KEYTRUDA (Biological) $17,161
- Vectibix (Biological) $9,650
- Lenvima (Drug) $151.74
- VERZENIO (Drug) $107.42
- VELCADE (Drug) $102.32
- Enhertu (Drug) $58.01
- CABOMETYX (Drug) $44.04
- Revlimid (Drug) $43.42
- Nubeqa (Drug) $39.83
- PREVNAR 20 (Biological) $36.59
- CABLIVI (Biological) $36.56
- IBRANCE (Drug) $27.05
- Trodelvy (Drug) $25.86
- CERDELGA (Drug) $24.65
- Alecensa (Biological) $23.17
- Avastin (Biological) $23.17
- ZEJULA (Drug) $21.44
- ALIMTA (Drug) $20.98
- Optune (Device) $20.60
- GILOTRIF (Drug) $20.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Germantown
Gregory Vidal, M.d, M.D
Medical Oncology — Payments: $416,944
Medical Oncology $416,944
Mr. Jason Chandler, M.d, M.D
Medical Oncology — Payments: $190,234
Medical Oncology $190,234
Daniel Vaena, Md, MD
Medical Oncology — Payments: $107,350
Medical Oncology $107,350
Ronald Lawson, Md, MD
Medical Oncology — Payments: $1,049
Medical Oncology $1,049
Dr. Jacob Adashek, Do, DO
Medical Oncology
Medical Oncology